Minerva Neurosciences (NASDAQ:NERV) Receives Coverage Optimism Score of 0.16

Headlines about Minerva Neurosciences (NASDAQ:NERV) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Minerva Neurosciences earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.1363398137756 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

NERV stock traded up $0.05 during midday trading on Wednesday, hitting $6.70. The stock had a trading volume of 80,700 shares, compared to its average volume of 200,087. The firm has a market capitalization of $257.68, a price-to-earnings ratio of -7.88 and a beta of 1.66. Minerva Neurosciences has a 52 week low of $4.80 and a 52 week high of $11.15.

NERV has been the topic of a number of research analyst reports. Zacks Investment Research raised Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.25 price target on the stock in a research report on Friday, March 16th. BidaskClub raised Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Finally, ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $12.75.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://baseballnewssource.com/2018/03/21/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-minerva-neurosciences-nerv-stock-price/1924920.html.

About Minerva Neurosciences

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.

Insider Buying and Selling by Quarter for Minerva Neurosciences (NASDAQ:NERV)

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.